World Vaccine Trials Congress Asia Day Two - 13 June 2012

last modified: 24 May '12

Please enable javascript to see more information on speakers

08.30
Registration and refreshments
08.50
Chairman’s opening remarks

REGULATORY CHALLENGES IN ASIA

09.00
Regulatory panel: Aligning clinical development of crucial vaccines with regulations to address Asia’s vaccine needs
Dr. Der-Yuan Wang at World Vaccine Congress Asia 2012

Dr. Der-Yuan Wang

Dr. Der-Yuan Wang has been working in the field of vaccines, blood products, in vitro diagnostics and cell-based products over fifteen years. Prior to joining the Taiwan Food and Drug Administration (Taiwan FDA) in Jan 2010, he worked at the Bureau ...

more..
Dr Hideki Hasegawa at World Vaccine Congress Asia 2012

Dr Hideki Hasegawa

Hideki Hasegawa, Director, Department of Pathology, at National Institute of Infectious Diseases (NIID), graduated from the Hokkaido University school of medicine in 1993 with M.D. and finished graduate school at Hokkaido University in 1997 with...

more..

  • Providing  a sustainable platform for exchanges on vaccine safety oversight and review
  • Fostering increased industry-governmental communication for future vaccine development
  • Understanding the regulatory framework of different Asian countries to accelerate vaccine licensing approval
     

09.40
Addressing the approval and safety surveillance of licensed vaccines in Taiwan
Dr. Der-Yuan Wang at World Vaccine Congress Asia 2012

Dr. Der-Yuan Wang

Dr. Der-Yuan Wang has been working in the field of vaccines, blood products, in vitro diagnostics and cell-based products over fifteen years. Prior to joining the Taiwan Food and Drug Administration (Taiwan FDA) in Jan 2010, he worked at the Bureau ...

more..

  • Resolving delays in application for approval of drug entry to market through a better understanding of Asian market needs
  • Assessing issues in BLA evaluation, lot release and post-market surveillance of vaccines in the market
  • Evaluating the current status and experiences from vaccine regulation and monitoring in Taiwan
     

10.10
Developing mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses
Dr Hideki Hasegawa at World Vaccine Congress Asia 2012

Dr Hideki Hasegawa

Hideki Hasegawa, Director, Department of Pathology, at National Institute of Infectious Diseases (NIID), graduated from the Hokkaido University school of medicine in 1993 with M.D. and finished graduate school at Hokkaido University in 1997 with...

more..

  • Harnessing mucosal immunity by mucosal adjuvants to induce cross-protective immunity against variant viruses
  • Resolving challenges in intranasal administration for new influenza vaccine
  • Evaluating clinical trial data results and identifying a suitable approach for regulatory approval in Japan
     

10.40
Morning refreshments, exhibition visit, academic poster showcase and on-floor demo

VACCINE DEVELOPMENT IN ASIA

11.10
Assessing challenges in designing effective vaccines against herpes virus-associated diseases
Prof. Rajiv Khanna at World Vaccine Congress Asia 2012

Prof. Rajiv Khanna

Prof. Rajiv Khanna obtained his doctorate degree from India and undertook his post-doctoral training at the Queensland Institute of Medical Research (QIMR), Brisbane Australia. He is currently appointed as the Director of the Australian Centre for...

  • Exploiting T cell immunity to enhance immune control of herpes virus infections
  • Developing clinical studies on T cell-based therapies to support development of therapeutic vaccines against herpes virus-associated diseases
  • Enhancing memory T cell response by combining innate and adaptive immunity 

  • › Prof. Rajiv Khanna, Director | Senior Principal Research Fellow, Australian Centre for Vaccine Development
11.40
Optimising cost-effective Japanese Encephalitis (JE) vaccine development in Asia
Associate Professor Dr Sutee Yoksan at World Vaccine Congress Asia 2012

  • Evaluating current development on inactivated and live molecular JE vaccine for the global population
  • Tapping on lessons learnt from producing the vaccine in Asia
  • Case study: Assessing the long term immunity of live attenuated Japanese encephalitis chimeric virus vaccine
     

12.10
Networking luncheon, exhibition visit, academic poster showcase and on-floor demo

SPECIAL MARKET FOCUS: VACCINE INNOVATION IN JAPAN

14.00
Innovative vaccine design: Important chemistry, manufacturing and controls (CMC) issues in adjuvant development
Prof Ken J. Ishii at World Vaccine Congress Asia 2012

Prof Ken J. Ishii

Prof. Ken Ishii is currently a Project leader at the Laboratory of Adjuvant Innovation at the National Institute for Biomedical Innovation (NIBIO) as well as a Professor at the Laboratory of Vaccine Science at the Immunology Frontier Research Center ...

more..

  • Uncovering new concepts and knowledge about innovative vaccine design; innate immunity and beyond
  • Tapping on advanced technologies of immune-manipulation and delivery system in Japan
  • Overcoming regulatory hurdles and harnessing the potential for adjuvants in Japan; key factors for very safe and efficacious vaccines

14.30
Reducing the vaccine gap between global and Japanese standards: Ongoing reformation of immunization practice in Japan
Dr Shin Sasaki at World Vaccine Congress Asia 2012

Dr Shin Sasaki

Shin Sasaki is Director of Vaccine Therapeutic Area, Medical Affairs Department of Pfizer Japan Specialty Care Business Unit, Tokyo, Japan. He has joined Pfizer in 2006 and expanded his role in Medical Affairs as well as Clinical Research Group in...

more..

  • Providing a general overview and history of immunization practice in Japan
  • Assessing the gap between global standard and local practice including ongoing effort to minimize the difference
  • Understanding the Japanese vaccine market landscape and its future direction
     

15.00
Developing vaccine business strategies in Daiichi Sankyo for contribution to Japanese vaccination programme
Dr Fumihiko Takeshita at World Vaccine Congress Asia 2012

Dr Fumihiko Takeshita

BUSINESS EXPERIENCES: April 2010 – Manager, Vaccine Business Planning Department, DaiichiSannkyo, Co. - Management of vaccine research and development ACADEMIC/CLINICAL EXPERIENCES: April 2010 – Visiting Professor of Medical Sciences (Microbiology ...

more..

  • Understanding the difference between the vaccination programme and system in Japan and other developed countries
  • Building strategic alliances with domestic and global vaccine manufacturers for contribution  to Japanese vaccination program
  • Developing multidisciplinary integration  strategies for creation of next-generation vaccines
     

15.30
Afternoon refreshments, exhibition visit, academic poster showcase and on-floor demo

UPDATES ON VACCINES FOR ASIA

16.00
Vaccine poster presentation: Research development from leading Asian and global academic institutions

In this session, leading global and Asian academic institutes will be showcasing their vaccine research capabilities. Each organisation will be highlighting the latest development in research for vaccines in the Asia Pacific region. They will share about their successful partnerships with global pharmaceuticals and biotech companies and how this relationship is critical in expediting vaccine drug development for prevalent diseases in Asia. 

    17.00
    Chairman’s closing remarks
    17.05
    End of conference day two

    Register for World Vaccine Congress Asia 2012 ›

    Get the World Vaccine Congress Asia 2012 brochure ›

    Back to top ›

    last modified: 24 May '12

    Developing effective production strategies for multi-vaccine manufacturing in Asia

    • Evaluating specific challenges associated with manufacturing different vaccines
    • Developing robust approaches to fully utilise production facility
    • Exploring the different strategies available for ensuring quality control and regulatory compliance

    Growing vaccine pipeline value through effective partnering and investment strategies in Asia

    Asia contains a wide variety of vaccine markets, each with different advantages due to cultural, economic and geographic differences. Identifying the right partners to develop vaccines from initial R&D through trials to commercialization requires a strategic and well defined approach.
    This workshop will assist participants in understanding how to approach the Asian market for external research and development and how to successfully build a pipeline through strategic partnerships.

    Transitioning existing biologics processes into single use technology platform to enable global deployment

    • Factors to consider before implementation: performance equivalency, quality, logistics and business needs
    • Evaluating which single-use equipment to utilize, considering cost and which stage should be implemented first
    • Examining before and after implementation for optimum efficiency

    Optimising cost-effective Japanese Encephalitis (JE) vaccine development in Asia

    • Evaluating current development on inactivated and live molecular JE vaccine for the global population
    • Tapping on lessons learnt from producing the vaccine in Asia
    • Case study: Assessing the long term immunity of live attenuated Japanese encephalitis chimeric virus vaccine

    Innovative vaccine design: Important chemistry, manufacturing and controls (CMC) issues in adjuvant development

    • Uncovering new concepts and knowledge about innovative vaccine design; innate immunity and beyond
    • Tapping on advanced technologies of immune-manipulation and delivery system in Japan
    • Overcoming regulatory hurdles and harnessing the potential for adjuvants in Japan; key factors for very safe and efficacious vaccines

    Innovative International Vaccine Developments

    Leading global and Asian biotechs, pharmas and research institutes will showcase their latest vaccine developments looking for potential partners globally and across Asia. Potential partnerships run from research and development to licensing and collaboration in vaccine commercialization.

    sponsor World Vaccine Congress Asia 2012 ›

    Sponsors
    Platinum sponsor
    GE Healthcare at World Vaccine Congress Asia 2012
    Gold Sponsor
    Merck Millipore at World Vaccine Congress Asia 2012
    Silver Sponsor
    Medicago Inc at World Vaccine Congress Asia 2012
    Bronze sponsor
    Finesse Solutions, LLC at World Vaccine Congress Asia 2012
    Bronze Sponsor
    ViroClinics Biosciences B.V. at World Vaccine Congress Asia 2012
    Innovative showcase sponsor
    Bavarian Nordic A/S at World Vaccine Congress Asia 2012
    Innovative biotech showcase sponsor
    Immune Targeting Systems (ITS) Ltd at World Vaccine Congress Asia 2012

    sponsors list ›